vPush

Disposable variable-dose pen injector

A flexible, cartridge-based pen for chronic therapies that require variable dosing and repeat injections.

vPush

Disposable variable-dose pen injector

A flexible, cartridge-based pen for chronic therapies that require variable dosing and repeat injections.

vPush

Disposable variable-dose pen injector

A flexible, cartridge-based pen for chronic therapies that require variable dosing and repeat injections.

Controlled manual injection with a smooth force profile

Cartridge-based system

Multi-dose capability for chronic therapy

Clear dose window and tactile feedback

Controlled manual injection with a smooth force profile

Cartridge-based system

Multi-dose capability for chronic therapy

Clear dose window and tactile feedback

For chronic therapies with frequent, flexible dosing

For chronic therapies with frequent, flexible dosing

Indications

Indications

Diabetes

Diabetes

GLP-1 / Weight Management

GLP-1 / Weight Management

Growth Disorders

Growth Disorders

Fertility

Fertility

Osteoporosis

Osteoporosis

Technical specifications

Technical specifications

Max dose

Max dose

0.80 ml

0.80 ml

Dose increment

Dose increment

0.01 ml

0.01 ml

Primary container

Primary container

Standard 3 ml cartridge according to ISO 11608-3

Standard 3 ml cartridge according to ISO 11608-3

Plunger

Plunger

8.5 mm or 11.5 mm

8.5 mm or 11.5 mm

Needles

Needles

Compatible with standard needles according to ISO 11608-2

Compatible with standard needles according to ISO 11608-2

Pre-validated packages in development

Pre-validated packages in development

dVise is developing regulatory-ready, pre-validated packages compatible with selected molecules. Biosimilars and close analogues can often follow the same route. For molecules or use cases outside the pre-validated paths, the platform is tuned to your molecule.

dVise is developing regulatory-ready, pre-validated packages compatible with selected molecules. Biosimilars and close analogues can often follow the same route. For molecules or use cases outside the pre-validated paths, the platform is tuned to your molecule.

Pre-validated packages

Regulatory-ready device platforms in development for selected molecules including testing, documentation to give your team a shorter path to adopt.

Insulin

Liraglutide (GLP-1)

Semaglutide (GLP-1)

Somatotropin (HGH)

Teriparatide

Follitropin alfa (FSH)

Expected availability: end of 2026 / start of 2027

Custom adaptations

Custom adaptations

For molecules or use cases outside the pre-validated paths, the platform is tuned to your molecule.

Contact us

©dVise Medtech Private Limited 2026

©dVise Medtech Private Limited 2026